AT7687
Low EvidenceA first-in-class GIPR antagonist peptide in early clinical development for obesity, designed as a once-weekly combination partner that adds weight loss and improves insulin sensitivity independent of appetite suppression.
What It Is
AT7687 is a first-in-class glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist peptide developed by Antag Therapeutics, a Danish biotech, for the treatment of obesity. Unlike the GIPR-agonist arm of tirzepatide, AT7687 blocks the GIP receptor — a genetically validated pathway implicated in fat storage, insulin resistance, and metabolic dysfunction. On January 8, 2026, Antag reported topline data from two studies. A Phase 1 first-in-human study, conducted in both healthy volunteers and people living with obesity, showed AT7687 was well tolerated and suitable for once-weekly subcutaneous dosing with no need for titration. A preclinical study in obese, insulin-resistant, pre-diabetic non-human primates randomized animals to placebo, cagrilintide, AT7687, or the combination for 42 days; the AT7687 plus cagrilintide combination produced robust, sustained low-double-digit-percentage weight loss that did not plateau, with the additional weight loss in the combination group reported to be independent of appetite suppression. The combination also improved body composition and insulin sensitivity without increasing the tolerability burden. Earlier data demonstrated additive weight loss when AT7687 was paired with a GLP-1 agonist, positioning the molecule as a versatile combination partner rather than a standalone therapy. Antag announced in April 2026 that it will present AT7687 data at the American Diabetes Association 86th Scientific Sessions (June 5-8, 2026, New Orleans), placing the GIPR-antagonism approach among the closely watched next-generation obesity mechanisms.
Regulatory Status
Phase 1 first-in-human data reported January 2026. Not approved in any jurisdiction.
Effective: 2026
View FDA SourceWhy Researchers Study It
AT7687 represents an emerging obesity drug class — GIPR antagonists — that takes the opposite pharmacological approach to the GIPR-agonist component of tirzepatide. Researchers study it because GIPR antagonism appears to add weight loss and improve insulin sensitivity and body composition through a mechanism independent of appetite suppression, making it an attractive combination partner for amylin agonists and GLP-1 agonists without compounding gastrointestinal tolerability burden.
Proposed Mechanisms
- Antagonizes (blocks) the GIP receptor, a pathway linked to fat storage and insulin resistance
- Adds weight loss independent of central appetite suppression in preclinical models
- Improves insulin sensitivity and body composition when combined with amylin or GLP-1 agonists
- Long-acting design enables once-weekly subcutaneous dosing without titration
Evidence Snapshot
| Study Type | Model | Outcome | Link |
|---|---|---|---|
| Human (Phase 1) | First-in-human study in healthy volunteers and people with obesity | Well tolerated; suitable for once-weekly subcutaneous dosing with no titration required | Source |
| Preclinical (non-human primate) | Obese, insulin-resistant, pre-diabetic NHP; 42-day randomized study vs placebo, cagrilintide, AT7687, and combination | AT7687 + cagrilintide produced robust, sustained low-double-digit % weight loss with no plateau; gains in insulin sensitivity and body composition independent of appetite suppression | Source |
Commonly Discussed Benefits
Researching AT7687? Track it, set reminders, and keep notes in the free app.
Safety & Cautions
- Only Phase 1 and preclinical data available; no Phase 2 efficacy in humans yet
- Human weight-loss magnitude not established — combination weight loss reported in animals
- Long-term safety and efficacy unknown
- Available only through clinical trial enrollment
- Not FDA-approved; not a compounding-eligible peptide
Comparisons
See how AT7687 compares to related peptides:
Calculator Tools
Use our research tools to explore dosing and reconstitution data:
Citations
Keep researching in the app
- Log AT7687 to your private tracker
- Set a dosing reminder
- Compare it side-by-side with your stack
Related Peptides
Tirzepatide
High EvidenceA dual GIP/GLP-1 receptor agonist FDA-approved for type 2 diabetes, weight management, and MASH with liver fibrosis.
Cagrilintide
High EvidenceA long-acting amylin analog studied for appetite regulation; NDA filed for CagriSema (cagrilintide + semaglutide) combination in December 2025, with FDA review expected in 2026.
Eloralintide
Medium EvidenceA selective, long-acting amylin receptor agonist in Phase 3 trials for obesity, offering a GLP-1-independent weight loss mechanism with up to 20.1% weight loss in Phase 2.
Maridebart Cafraglutide (MariTide)
Medium EvidenceAmgen's once-monthly injectable GIP receptor antagonist and GLP-1 receptor agonist, showing up to 20% weight loss in phase 2 trials with a unique mechanism that blocks GIP while activating GLP-1.